Synovial tissue analysis in clinical trials

Barry Bresnihan; Dominique Baeten; Gary S. Firestein; Oliver M. Fitzgerald; Danielle M. Gerlag; Jasper J. Haringman; Iain B. McInnes; Richard J. Reece; Malcolm D. Smith; Ann-Kristin Ulfgren; Douglas J. Veale; Paul Peter Tak

Synovial tissue analysis in clinical trials

Barry Bresnihan, Dominique Baeten, Gary S. Firestein, Oliver M. Fitzgerald, Danielle M. Gerlag, Jasper J. Haringman, Iain B. McInnes, Richard J. Reece, Malcolm D. Smith, Ann-Kristin Ulfgren, Douglas J. Veale, Paul Peter Tak

Research output: Contribution to journal › Article › Academic › peer-review

26 Citations (Scopus)

Abstract

Synovial tissue analysis has considerable potential for future randomized controlled trials (RCT). The synovial membrane is the target tissue in treatment strategies of rheumatoid arthritis and other arthropathies. Effective modulation of synovitis is critical when attempting to control symptoms and signs, to prevent joint damage, and to maintain function. In RCT, the systematic evaluation of changes in synovial tissue after commencing treatment enables identification of an early therapeutic effect, using relatively small numbers of patients. This special interest group is working on establishing the evidence to have this endpoint meet the OMERACT filter criteria

Original language	English
Pages (from-to)	2481-2484
Journal	Journal of rheumatology
Volume	32
Issue number	12
Publication status	Published - 2005

Cite this

@article{0faf40ed64d74414a5f189a242e9661c,

title = "Synovial tissue analysis in clinical trials",

abstract = "Synovial tissue analysis has considerable potential for future randomized controlled trials (RCT). The synovial membrane is the target tissue in treatment strategies of rheumatoid arthritis and other arthropathies. Effective modulation of synovitis is critical when attempting to control symptoms and signs, to prevent joint damage, and to maintain function. In RCT, the systematic evaluation of changes in synovial tissue after commencing treatment enables identification of an early therapeutic effect, using relatively small numbers of patients. This special interest group is working on establishing the evidence to have this endpoint meet the OMERACT filter criteria",

author = "Barry Bresnihan and Dominique Baeten and Firestein, {Gary S.} and Fitzgerald, {Oliver M.} and Gerlag, {Danielle M.} and Haringman, {Jasper J.} and McInnes, {Iain B.} and Reece, {Richard J.} and Smith, {Malcolm D.} and Ann-Kristin Ulfgren and Veale, {Douglas J.} and Tak, {Paul Peter}",

year = "2005",

language = "English",

volume = "32",

pages = "2481--2484",

journal = "Journal of rheumatology",

issn = "0315-162X",

publisher = "Journal of Rheumatology",

number = "12",

}

TY - JOUR

T1 - Synovial tissue analysis in clinical trials

AU - Bresnihan, Barry

AU - Baeten, Dominique

AU - Firestein, Gary S.

AU - Fitzgerald, Oliver M.

AU - Gerlag, Danielle M.

AU - Haringman, Jasper J.

AU - McInnes, Iain B.

AU - Reece, Richard J.

AU - Smith, Malcolm D.

AU - Ulfgren, Ann-Kristin

AU - Veale, Douglas J.

AU - Tak, Paul Peter

PY - 2005

Y1 - 2005

N2 - Synovial tissue analysis has considerable potential for future randomized controlled trials (RCT). The synovial membrane is the target tissue in treatment strategies of rheumatoid arthritis and other arthropathies. Effective modulation of synovitis is critical when attempting to control symptoms and signs, to prevent joint damage, and to maintain function. In RCT, the systematic evaluation of changes in synovial tissue after commencing treatment enables identification of an early therapeutic effect, using relatively small numbers of patients. This special interest group is working on establishing the evidence to have this endpoint meet the OMERACT filter criteria

AB - Synovial tissue analysis has considerable potential for future randomized controlled trials (RCT). The synovial membrane is the target tissue in treatment strategies of rheumatoid arthritis and other arthropathies. Effective modulation of synovitis is critical when attempting to control symptoms and signs, to prevent joint damage, and to maintain function. In RCT, the systematic evaluation of changes in synovial tissue after commencing treatment enables identification of an early therapeutic effect, using relatively small numbers of patients. This special interest group is working on establishing the evidence to have this endpoint meet the OMERACT filter criteria

M3 - Article

C2 - 16331792

SN - 0315-162X

VL - 32

SP - 2481

EP - 2484

JO - Journal of rheumatology

JF - Journal of rheumatology

IS - 12

ER -